Receive our top articles each week direct to your inbox
by Valentina Lencautan Published on 18th Jun 2015
by Valentina Lencautan Published on 18th June 2015
In an article published in nature.com, Erika C. Hayden looks at one of
the most promising age delaying drugs, rapamycin, and metmorfin, the
legitimacy of which will be discussed in the future meeting between
scientists and US Food and Drug Administration on June 24.
Physicians conducting the research at the Albert Einstein College of Medicine in New York argue it is time for life-extending drugs and treatments that could
prolong a person's healthy years to be approved by the government.
Dr. Nir Barzilai sustains this can be done by slowing down the
process of ageing: “What we want to show is that if we delay
ageing, that's the best way to delay disease.”
new trial called TAME (Targeting Ageing with Metformin) will be
carried out over 5-7 years, in which thousands of patients who suffer
from conditions such as cancer, heart disease and cognitive
impairment will be given metformin. If successful in proving that
the drug can forestall ageing, the trial would prove ageing to be a
disorder and would accelerate raising funds for further research. A significant development.
similar test, sponsored by the NIA, titled Interventions Testing
Program, discovered that drug rapamycin not only prolonged life in
mice, but also, in the form of an influenza vaccination,
managed to strengthen the immune system of elderly people.
a drug that has been in use for 60 years, known to regulate glucose
by the liver and increase sensitivity to insulin, already has a
history in prolonging lifespan in worms and mouse strains. The test,
combined with data processing hopes to demonstrate metmorfin can have
a significant impact upon the ageing process in people and the development of treatments to increase healthy lifespan. Read the full article here